Memo Page 1
Memo Page 2
Print-friendly pdf version (240 K) of Avigan memo (courtesy of psychrights.org)
Memo Page 1
Memo Page 2
Print-friendly pdf version (240 K) of Trontell memo (courtesy of psychrights.org)
Page 1: Executive Summary
Page 2: Recommendations
Page 3: Background; Methods
Page 5: Results; Bupropion (Wellbutrin, GlaxoSmithKline)
Page 6: Mirtazapine (Remeron, Organon); Fluoxetine (Prozac, Lilly)
Page 7: Nefazodone (Serzone, Bristol Myers Squibb)
Page 8: Fluvoxamine (Luvox, Solvay); Sertraline (Zoloft, Pfizer)
Page 9: Citalopram (Celexa, Forest)
Page 10: Paroxetine (Paxil, GlaxoSmithKline); Venlafaxine (Effexor, Wyeth)
Page 12: Risk estimates - Analysis of attributable risk; Table 1. Attributable risks (incidence rate differences) per patient-year for suicide-related events in pediatric trials; Table 2. Attributable risks (incidence rate differences) per patient-year for serious suicide-related events in pediatric trials
Page 13: Analysis of relative risk
Page 14: Discussion and Conclusions; Table 3. Combined incidence rate ratios for suicide-related events and serious suicide-related events
Page 17: Recommendations
Page 18: Appendix Table 1. Summary of pediatric clinical trial data on suicidal adverse events
Page 19: Appendix Table 2. Rates of suicidal adverse events, per patient-year, in pediatric clinical trials
Page 20: Appendix Table 3. Listing of all patients with suicide-related events in pediatric antidepressant drug trials; Mirtazapine & Fluoxetine
Page 21: Nefazodone, Fluvoxamine, & Sertraline
Page 22: Citalopram
Page 23: Paroxetine
Page 24: Venlafaxine
Page 25: Bupropion (no cases)
Page 28: Appendix table 5. Summary of efficacy findings from eight pediatric antidepressant development programs
Print-friendly pdf version (3.2 MB) of Mosholder report (courtesy of psychrights.org)
return to July 26, 2004 infomail
see also GSK Strategy of Concealment